Adarx Pharmaceuticals Inc.

Adarx Pharmaceuticals Inc. company information, Employees & Contact Information

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics.  ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases.  We are well-financed by a syndicate of renowned VC firms. ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.

Company Details

Employees
77
Founded
-
Address
5871 Oberlin Drive, San Diego,ca 92121,united States
Phone
858-283-9472
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
adarx.com
Keywords
jobs.
HQ
San Diego, CA
Looking for a particular Adarx Pharmaceuticals Inc. employee's phone or email?

Adarx Pharmaceuticals Inc. Questions

News

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair - Yahoo Finance

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair Yahoo Finance

AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas - PR Newswire

AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas PR Newswire

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing - Bain Capital

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing Bain Capital

ADARx Inks $335M Agreement with AbbVie - San Diego Business Journal

ADARx Inks $335M Agreement with AbbVie San Diego Business Journal

AbbVie pays ADARx $335M cash for next-gen siRNA options - Fierce Biotech

AbbVie pays ADARx $335M cash for next-gen siRNA options Fierce Biotech

AbbVie bets $335M upfront for ADARx's gene-silencing tech - FirstWord Pharma

AbbVie bets $335M upfront for ADARx's gene-silencing tech FirstWord Pharma

AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal - BioSpace

AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal BioSpace

AbbVie & ADARx Partner on Next-Gen siRNA Therapeutics - Contract Pharma

AbbVie & ADARx Partner on Next-Gen siRNA Therapeutics Contract Pharma

Yes siRNA: Adarx/Abbvie tie-up worth “several billion” dollars - BioWorld MedTech

Yes siRNA: Adarx/Abbvie tie-up worth “several billion” dollars BioWorld MedTech

AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies - PMLiVE

AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies PMLiVE

ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Business Wire

ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic Business Wire

ADARx doses first subject in Phase III trial of ADX-324 for HAE - Clinical Trials Arena

ADARx doses first subject in Phase III trial of ADX-324 for HAE Clinical Trials Arena

AbbVie stakes $335M on a startup’s RNAi drugs - BioPharma Dive

AbbVie stakes $335M on a startup’s RNAi drugs BioPharma Dive

AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies - Dermatology Times

AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies Dermatology Times

AbbVie expands siRNA push with $335m ADARx deal - Pharmaceutical Technology

AbbVie expands siRNA push with $335m ADARx deal Pharmaceutical Technology

RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi ‘to the next level’ - Endpoints News

RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi ‘to the next level’ Endpoints News

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics - Yahoo Finance

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics Yahoo Finance

ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - Business Wire

ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 Business Wire

AbbVie doubles down on siRNA with $335M upfront bet on ADARx - Endpoints News

AbbVie doubles down on siRNA with $335M upfront bet on ADARx Endpoints News

ADARx secures $200m to advance clinical programmes - Pharmaceutical Technology

ADARx secures $200m to advance clinical programmes Pharmaceutical Technology

RNA biotech ADARx hauls in $200M, almost doubling 2 previous raises combined - Fierce Biotech

RNA biotech ADARx hauls in $200M, almost doubling 2 previous raises combined Fierce Biotech

AbbVie and ADARx Pharmaceuticals Announce Collaboration - citybiz

AbbVie and ADARx Pharmaceuticals Announce Collaboration citybiz

Fresh off massive fundraising, ADARx preps 3rd clinical program and mulls IPO - Fierce Biotech

Fresh off massive fundraising, ADARx preps 3rd clinical program and mulls IPO Fierce Biotech

ADARx Pharmaceuticals doses first cohort in Phase I HAE therapy trial - Clinical Trials Arena

ADARx Pharmaceuticals doses first cohort in Phase I HAE therapy trial Clinical Trials Arena

Billions to play for in AbbVie and ADARx siRNA tie-up - The Pharma Letter

Billions to play for in AbbVie and ADARx siRNA tie-up The Pharma Letter

AbbVie paying $355M, potentially billions more, in deal for new RNA tech - Crain's Chicago Business

AbbVie paying $355M, potentially billions more, in deal for new RNA tech Crain's Chicago Business

AbbVie and ADARx to develop siRNA therapeutics for multiple disease areas - Pharmaceutical Business review -

AbbVie and ADARx to develop siRNA therapeutics for multiple disease areas Pharmaceutical Business review -

ADARx Pharmaceuticals Appoints Christopher Prentiss As CFO - citybiz

ADARx Pharmaceuticals Appoints Christopher Prentiss As CFO citybiz

ADARx Nets $200M for Lead siRNA Drug Candidates - Inside Precision Medicine

ADARx Nets $200M for Lead siRNA Drug Candidates Inside Precision Medicine

San Diego biotech lands $46M for treatment targeting life-threatening swelling attacks - San Diego Union-Tribune

San Diego biotech lands $46M for treatment targeting life-threatening swelling attacks San Diego Union-Tribune

Adarx to use $200M in financing to advance its clinical programs - Angioedema News

Adarx to use $200M in financing to advance its clinical programs Angioedema News

AbbVie (ABBV) Enters Agreement with ADARx for RNA Therapies - GuruFocus

AbbVie (ABBV) Enters Agreement with ADARx for RNA Therapies GuruFocus

AbbVie (ABBV) Collaborates with ADARx to Advance siRNA Therapeutics | ABBV Stock News - GuruFocus

AbbVie (ABBV) Collaborates with ADARx to Advance siRNA Therapeutics | ABBV Stock News GuruFocus

Adarx's HAE Therapy ADX-324 Enters Phase 1 Clinical Trial Testing... - Angioedema News

Adarx's HAE Therapy ADX-324 Enters Phase 1 Clinical Trial Testing... Angioedema News

OrbiMed, Lilly Asia Ventures chip into ADARx's $75M round to take RNA tech into the clinic - Fierce Biotech

OrbiMed, Lilly Asia Ventures chip into ADARx's $75M round to take RNA tech into the clinic Fierce Biotech

ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025 - The Manila Times

ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025 The Manila Times

Top Adarx Pharmaceuticals Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant